Asset Details
Do you wish to reserve the book?
The role of NETosis in breast cancer: mechanistic insights and biomarker potential
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The role of NETosis in breast cancer: mechanistic insights and biomarker potential
Do you wish to request the book?
The role of NETosis in breast cancer: mechanistic insights and biomarker potential
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The role of NETosis in breast cancer: mechanistic insights and biomarker potential
2025
Overview
Neutrophil extracellular trap formation (NETosis), previously described as an effector host defense mechanism, is more frequently associated with cancer-driven inflammation and tumor development. In the case of breast cancer, NETosis assists with several oncogenic processes, including epithelial-mesenchymal transition, immune evasion, organotropic metastasis, angiogenesis, and resistance to therapy. The current study summarizes the evidence of the mechanistic role of NETs in breast cancer and their potential to act as a diagnostic, prognostic, or therapeutic biomarker. Like many other promising candidates for novel prognostic or diagnostic biomarkers, citrullinated histone H3 (citH3), myeloperoxidase-DNA (MPO-DNA) complexes, and circulating cell-free DNA (cfDNA) need further validation to be functional. However, there is some evidence suggesting clinical relevance. Like many candidate therapeutic indices, several therapies are exploring targeting NETosis, including deoxyribonuclease I (DNase I) and peptidyl arginine deiminase 4 (PAD4) inhibitors, as a clinical intervention. However, methodological differences across studies and a lack of standardized detection of NETs are likely impeding future findings. Future insight into the efficiency of detection methods and consistency of experimental design will be beneficial for transferring NETosis to the clinic.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Biomarkers, Tumor - metabolism
/ Biomedical and Life Sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ DNA
/ Extracellular Traps - metabolism
/ Female
/ Histones
/ Humans
/ Neutrophil extracellular traps (NETs)
/ Oncology
/ Protein-Arginine Deiminase Type 4 - antagonists & inhibitors
/ Proteins
/ Review
We currently cannot retrieve any items related to this title. Kindly check back at a later time.